Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 5,601–5,700 of 15,747
Wallace, H., & Mount, P. F. (2021) · Internal Medicine Journal · doi:10.1111/imj.15636 · Cited by 15
Németh, D., Vágó, H., Tóthfalusi, L., Ulakcsai, Z., Becker, D. A., Szabo, Z., Rojkovich, B., Merkely, B. P., & Nagy, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.960001 · Cited by 17
Jennewein, M. F., Schultz, M. D., Beaver, S., Battisti, P., Bakken, J., Hanson, D. J., Akther, J., Zhou, F., Mohamath, R., Singh, J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.007 · Cited by 25
Vaccination against SARS‐CoV‐2 and psoriasis: the three things every dermatologist should know
Diotallevi, F., Campanati, A., Radi, G., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17256 · Cited by 15
Trimeric, APC-Targeted Subunit Vaccines Protect Mice against Seasonal and Pandemic Influenza
Tjärnhage, E., Brown, D., Bogen, B., Andersen, T. K., & Grødeland, G. (2023) · Journal of Virology · doi:10.1128/jvi.01694-22 · Cited by 18
“Moderna (Spikevax) (47) and Pfizer-BioNTech (Comirnaty) (48) and the DNA vaccine”
BackgroundSen, P., Lilleker, J. B., Agarwal, V., Kardeş, S., Milchert, M., Gheita, T. A., Salim, B., Velikova, T. V., Gracia‐Ramos, A. E., Parodis, I., et al. (2022) · Indian Journal of Rheumatology · doi:10.4103/injr.injr_221_21 · Cited by 20
“[16, 17] These reassuring results may ameliorate some of the concerns regarding postvaccination adverse effects in patients with AIRDs.”
Novel coronavirus mutations: Vaccine development and challenges
Luo, W.-R., Wu, X., Wang, W., Yu, J., Chen, Q., Zhou, X., Huang, X., Pan, H., Liu, Z., Gao, Y., et al. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105828 · Cited by 19
“nanoparticle-based vaccines are currently under development: lipid nanoparticles (LNPs)[74, 127], 398 virus-like particles (VLPs)[128, 129], protein nanoparticles[130, 131], polymer nanoparticles[132], 399 liposomes[133], and micelles[134].”
BackgroundRovida, F., Esposito, G. L., Rissone, M., Novelli, V., Cutti, S., Muzzi, A., Rona, C., Bertoli, E., Daglio, M., Piralla, A., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.06.028 · Cited by 17
Tebas, P., Patel, A. R., Agnes, J. T., Parzych, E. M., Baer, A. L., Caturla, M., Ghosh, S., Purwar, M., Bedanova, N. M., Tsang, C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03969-0 · Cited by 18
“Nucleic acid technologies, including notably mRNA vaccines, had an instrumental role in mitigating the spread of SARS-CoV-2 and reducing COVID-19 disease morbidity and mortality 1,2 .”
Simplified Mathematical Modelling of Uncertainty: Cost-Effectiveness of COVID-19 Vaccines in Spain
Marco-Franco, J., Barros, P. P., González-de-Julián, S., Sabat, I., & Vivas-Consuelo, D. (2021) · Mathematics · doi:10.3390/math9050566 · Cited by 17
Duong, M. C., Nguyen, H. T., & Thuy, D. B. (2021) · Infection and Chemotherapy · doi:10.3947/ic.2021.0122 · Cited by 14
Mayer, L., Weskamm, L. M., Fathi, A., Kono, M., Heidepriem, J., Krähling, V., Mellinghoff, S. C., Ly, M. L., Friedrich, M., Hardtke, S., et al. (2024) · npj Vaccines · doi:10.1038/s41541-023-00801-z · Cited by 19
Ferraresso, F., Badior, K. E., Seadler, M. S., Zhang, Y., Wietrzny, A., Cau, M. F., Haugen, A., Rodriguez, G. G., Dyer, M., Cullis, P. R., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101314 · Cited by 21
Incidence and management of the main serious adverse events reported after COVID ‐19 vaccination
Padilla‐Flores, T., Sampieri, A., & Vaca, L. A. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1224 · Cited by 20
“12,13”
Caldwell, J. M., de Lara-Tuprio, E. P., Teng, T. R. Y., et al. (2021) · medRxiv · doi:10.1101/2021.01.14.21249848 · Cited by 15
Zhao, Y., Li, R., Liu, P., Wang, J., Cui, Y., Ma, Y., Cao, Z., Cui, M., Luozhong, S., Wagner, E. K., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01577-4 · Cited by 30
“Even FDA-approved LNP vectors, such as BNT162b2 from Pfizer-BioNTech COVID-19 vaccines, exhibit reactogenicity, as observed in its phase 2/3 trial safety results 7 .”
Figueiredo, J. C., Hirsch, F. R., Kushi, L. H., Nembhard, W. N., Crawford, J. M., Mantis, N. J., Finster, L. J., Merin, N. M., Merchant, A. A., Reckamp, K. L., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac171 · Cited by 15
“By December 2020, Pfizer-BioNTech [3] and Moderna/NIAID [4] had begun clinical trials in healthy populations on their respective mRNA SARS-CoV-2 vaccines, and they reported >94% short-term vaccine efficacy against hospitalization and mortality, with no evidence of increased incidence of major adverse events.”
Self-citationDamasceno, D. H. P., Amaral, A. A., Silva, C. A., & Silva, A. C. S. E. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210902094254 · Cited by 17
Immune responses to SARS-CoV-2 infection and vaccination in children
Brodin, P. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101794 · Cited by 17
Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer
Body, A. L., Lal, L., Srihari, S., MacIntyre, C. R., Buttery, J. P., Ahern, E. S., Opat, S., Leahy, M. F., Hamad, N., Milch, V., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126547 · Cited by 18
Hu, S., Xiong, C., Zhao, Y., Yuan, X., & Wang, X. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.056 · Cited by 15
“0 % efficacy against symptomatic infection and 100 % efficacy in preventing severe-critical disease [3,40], there is increasing skepticism toward the real-world effectiveness of vaccines [32].”
SARS-CoV-2: Overview and Its Impact on Oral Health
Ting, M., & Suzuki, J. B. (2021) · Biomedicines · doi:10.3390/biomedicines9111690 · Cited by 17
“The BNT162b2 mRNA vaccine (Pfizer) may provide early protection 12 days after first dose [68,69], and is approximately 95% efficient against COVID-19 seven days after the second dose.”
BackgroundMyocarditis in the Setting of Recent COVID-19 Vaccination
Onderko, L. L., Starobin, B., Riviere, A., Hohl, P. K., Phillips, C. T., Morgan, R. B., Welsh, A. C., Francis, S. A., & Afari, M. E. (2021) · Case Reports in Cardiology · doi:10.1155/2021/6806500 · Cited by 16
Pourcher, V., Belin, L., Soulié, C., Rosenzwajg, M., Marot, S., Lacombe, K., Valin, N., Pialoux, G., Câlin, R., Palacios, C., et al. (2022) · AIDS · doi:10.1097/qad.0000000000003300 · Cited by 16
Wang, B., Zhao, J., Liu, S., Feng, J., Luo, Y., He, X., Wang, Y., Ge, F., Wang, J., Ye, B., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2079426 · Cited by 13
“have designed and manufactured vaccines [51,52] and monoclonal antibodies [33,34] for specific variants of the SARS-CoV-2 virus.”
Czarnowska, A., Tarasiuk, J., Zajkowska, O., et al. (2022) · Vaccines · doi:10.3390/vaccines10050763 · Cited by 15
“The frequency of adverse events was not higher when compared to that of the general population [15].”
BackgroundDeciphering Fc-effector functions against SARS-CoV-2
Beaudoin-Bussières, G., & Finzi, A. (2024) · Trends in Microbiology · doi:10.1016/j.tim.2024.01.005 · Cited by 19
Nanocarriers for inhaled delivery of RNA therapeutics
Huayamares, S. G., Zenhausern, R., & Loughrey, D. (2024) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2024.100200 · Cited by 17
Determining the Optimal SARS-CoV-2 mRNA Vaccine Dosing Interval for Maximum Immunogenicity
Asamoah-Boaheng, M., Goldfarb, D. A., Prusinkiewicz, M. A., Golding, L., Karim, M. E., Barakauskas, V., Wall, N., Jassem, A. N., Marquez, A. C., MacDonald, C., et al. (2023) · Cureus · doi:10.7759/cureus.34465 · Cited by 16
“SARS-CoV-2 vaccines were subsequently developed, with high efficacy for preventing short-term disease [1,2].”
BackgroundNatural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability
Graydon, E. K., Conner, T. L., Dunham, K., Olsen, C. H., Goguet, E., Coggins, S. A., Rekedal, M. S., Samuels, E. C., Jackson-Thompson, B. M., Moser, M. S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1225025 · Cited by 19
“Although initial formulations of mRNA vaccines have been tested since 1995 (1), the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) was the first United States Food and Drug Administration (FDA) approved mRNA vaccine.”
BackgroundInfluentialAnti‐COVID‐19 measurements for hidradenitis suppurativa patients
Giamarellos‐Bourboulis, E. J., Bettoli, V., Jemec, G. B. E., del Mármol, V., Marzano, A. V., Prens, E. P., Tzellos, T., & Zouboulis, C. C. (2021) · Experimental Dermatology · doi:10.1111/exd.14339 · Cited by 16
Mokuda, S., Watanabe, H., Kohno, H., Ishitoku, M., Araki, K., Hirata, S., & Sugiyama, E. (2022) · Cytotechnology · doi:10.1007/s10616-022-00540-4 · Cited by 17
“Recently, the novel coronavirus disease 2019 pandemic, which has been ongoing since December 2019, has led to the development of innovative mRNA vaccines such as BNT162b2 and mRNA-1273, containing N1-methylpseudouridine-5′-triphosphate (m1ψ) (Polack et al. 2020; Baden et al. 2021).”
BackgroundWang, Q., Nair, M. S., Anang, S., Zhang, S., Nguyen, H., Huang, Y., Liu, L., Ho, D. D., & Sodroski, J. G. (2021) · iScience · doi:10.1016/j.isci.2021.103393 · Cited by 15
“Multiple vaccine approaches employing SARS-CoV-2 spike (S) glycoprotein immunogens have demonstrated significant clinical efficacy (Anderson et al., 2020; AstraZeneca, 2021; Baden et al., 2021; Johnson, 2021; Novavax, 2021; Polack et al., 2020; Voysey et al., 2021; Xia et al., 2021).”
A vaccine delivery system promotes strong immune responses against SARS‐CoV‐2 variants
Lei, Z., Zhu, L., Pan, P., Ruan, Z., Gu, Y., Xia, X., Wang, S., Ge, W., Yao, Y., Luo, F., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28475 · Cited by 16
“S (Janssen's), have been authorized for emergency use.35,36 Two mRNA‐ based vaccines, Moderna and Pfizer‐BioNTech, provide a high level of protection against COVID‐19.37,38 Protein subunit vaccines containing S protein or RBD as the antigen, have been approved as an option for the COVID‐19 booster shot.39 However, cur…”
BackgroundInfluentialPresby, D. M., & Capodilupo, E. R. (2022) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00420.2021 · Cited by 15
Retrospective study on the safety of COVID ‐19 vaccination in myasthenia gravis
Pincheira, A. U., Alnajjar, S., Katzberg, H. D., Barnett, C., Daniyal, L., Rohan, R., & Bril, V. (2022) · Muscle & Nerve · doi:10.1002/mus.27657 · Cited by 15
Zhang, S., Chen, S., Xiao, G., Zhao, M., Li, J., Dong, W., Hu, J., Yuan, T., Li, Y., & Liu, L. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16786-y · Cited by 16
Frasca, L., Ocone, G., & Palazzo, R. (2023) · Pathogens · doi:10.3390/pathogens12020233 · Cited by 21
“Currently, the real effectiveness of mRNA vaccines against Omicron variants is unclear and seems to be lower than that obtained with previous variants, even with a fourth dose [9,10].”
ResultCOVID-19 vaccines: Frequently asked questions and updated answers
Lefebvre, M., Vignier, N., Pitard, B., Botelho-Nevers, É., Wyplosz, B., Cohen, R., & Épaulard, O. (2021) · Infectious Diseases Now · doi:10.1016/j.idnow.2021.02.007 · Cited by 17
Bignon, E., Marazzi, M., Grandemange, S., & Monari, A. (2022) · Chemical Science · doi:10.1039/d2sc00108j · Cited by 13
Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know?
Parra-Lucares, A., Toro, L., Weitz-Muñoz, S., & Ramos, C. (2021) · Viruses · doi:10.3390/v13122493 · Cited by 16
Mori, Y., Uchida, N., Harada, T., Katayama, Y., Wake, A., Iwasaki, H., Eto, T., Morishige, S., Fujisaki, T., Ito, Y., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26769 · Cited by 14
Mohammadi, G., Koranni, Z. S., & Jebali, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108231 · Cited by 16
“Moreover, the success of developing mRNA-based COVID-19 vaccines opens a new window to vaccine design [7,8].”
Veenstra, J. J., Wang, J., McKinnon-Maksimowicz, K., Liu, T., Zuniga, B., Hamzavi, I. H., Zhou, L., & Mi, Q.-S. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220736 · Cited by 15
SARS-CoV-2 vaccines: anamnestic response in previously infected recipients
Purushotham, J. N., van Doremalen, N., & Munster, V. J. (2021) · Cell Research · doi:10.1038/s41422-021-00516-7 · Cited by 14
Singh, R., Li, J., Parmar, U., Jeng, B., & Jhanji, V. (2022) · British Journal of Ophthalmology · doi:10.1136/bjo-2022-322512 · Cited by 13
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
Rieckmann, P., Centonze, D., Giovannoni, G., Hua, L. H., Oreja‐Guevara, C., Selchen, D. H., Sørensen, P. S., Vermersch, P., Wiendl, H., Salloukh, H., et al. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211058298 · Cited by 15
Cao, X., Manhas, A., Chen, Y. M., Caudal, A., Mondéjar‐Parreño, G., Zhu, W., Liu, W., Kong, X., Zeng, W., Liu, L., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq0143 · Cited by 22
COVID-19 vaccination acceptance in the canton of Geneva: a cross-sectional population-based study
Wisniak, A., Baysson, H., Pullen, N., Nehme, M., Pennacchio, F., Zaballa, M.-E., Guessous, I., & Stringhini, S. (2021) · Swiss Medical Weekly · doi:10.4414/smw.2021.w30080 · Cited by 17
Streif, S., Neckermann, P., Spitzenberg, C., Weiß, K. T., Hoecherl, K., Kulikowski, K., Hahner, S., Nölting, C., Einhauser, S., Peterhoff, D., et al. (2023) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-04548-3 · Cited by 18
Kim, S., Hwang, I., Ko, M., Kwon, Y., & Lee, Y.-K. (2022) · Osong Public Health and Research Perspectives · doi:10.24171/j.phrp.2022.0122 · Cited by 14
Mateo‐Urdiales, A., Sacco, C., Petrone, D., Bella, A., Riccardo, F., Manso, M. D., Bressi, M., Siddu, A., Brusaferro, S., Palamara, A. T., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.36854 · Cited by 15
Kim, K. H., Bhujel, R., Maharjan, R., Lee, J. C., Jung, H. S., Kim, H. J., Kim, N. A., & Jeong, S. H. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.07.013 · Cited by 21
Rosati, M., Agarwal, M., Hu, X., Devasundaram, S., Stellas, D., Chowdhury, B., Bear, J., Burns, R., Donohue, D. E., Pessaint, L., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009701 · Cited by 14
Ferguson, J., Murugesan, K., Banaei, N., & Liu, A. Y. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.06.054 · Cited by 15
Kim, T., Park, S. Y., Yu, S., Park, J. W., Lee, E. J., Jeon, M. H., Kim, T. H., & Choo, E. J. (2021) · Vaccines · doi:10.3390/vaccines9060648 · Cited by 16
Nicastro, E., Ebel, N. H., Kehar, M., Czubkowski, P., Ng, V. L., Michaels, M. G., Lobritto, S., Martinez, M., & Indolfi, G. (2021) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003339 · Cited by 16
“As of September 2021, four COVID-19 vaccines were available for use (Pfizer-BioNTech (135), Moderna (136), AstraZeneca (137), Janssen-Johnson & Johnson (138)).”
BackgroundMethodPu, J., He, X., Xu, W., Wang, C., Lan, Q., Hua, C., Wang, K., Lu, L., & Jiang, S. (2022) · Viruses · doi:10.3390/v14030489 · Cited by 17
Major cardiac concerns in therapy and vaccinations for COVID-19
Junapudi, S. S., Junapudi, S., Ega, K., & Chidipi, B. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100102 · Cited by 15
“It is worth mentioning that the vaccines supported by Pfizer [54], Moderna [55], and AstraZeneca [56] have included the elderly, cardiac patients, diabetics, severely obese individuals, Afro-descendants, and Latinos.”
COVID-19 vaccines: Update of the vaccines in use and under development
Marta, R. A., Nakamura, G. E. K., Aquino, B. D. M., & Bignardi, P. R. (2022) · Vacunas (English Edition) · doi:10.1016/j.vacun.2022.06.003 · Cited by 17
“Sputnik V - the first registered vaccine against COVID-19.”
InfluentialMultibacillary leprosy unmasked by COVID-19 vaccination
Aponso, S., Loh, C. H., Wei, Y. Y., Salahuddin, S. A., & Pan, J. Y. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.11.011 · Cited by 15
“The Pfizer-BioNTech BNT162b2 vaccine contains lipid nanoparticle-formulated, nucleoside-modified RNA, which encodes for the SARS-CoV-2 spike protein.(2) This triggers an immunologic response, leading to the formation of SARS-CoV-2 neutralizing antibodies.”
Delivery challenges for CRISPR—Cas9 genome editing for Duchenne muscular dystrophy
Padmaswari, M. H., Agrawal, S., Jia, M. S., Ivy, A., Maxenberger, D. A., Burcham, L. A., & Nelson, C. E. (2023) · Biophysics Reviews · doi:10.1063/5.0131452 · Cited by 19
Appel, K. S., Nürnberger, C., Bahmer, T., Förster, C., Polidori, M. C., Kohls, M., Kraus, T., Hettich-Damm, N., Petersen, J., Blaschke, S., et al. (2024) · Infection · doi:10.1007/s15010-024-02226-9 · Cited by 20
“Vaccination is a key protective factor for acute severity [36, 37], but its effect on PCS varies across studies [38].”
The mRNA vaccine platform for veterinary species
Fazel, F., Doost, J. S., Raj, S., Boodhoo, N., Karimi, K., & Sharif, S. (2024) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2024.110803 · Cited by 22
Lipid-Based Nanocarriers in Renal RNA Therapy
Su, C.-T., See, D. H. W., & Huang, J. (2022) · Biomedicines · doi:10.3390/biomedicines10020283 · Cited by 16
“Both the BNT162b2 and mRNA-1273 vaccines employ lipid nanocarriers to facilitate the delivery of antigenic mRNA [10,11].”
BackgroundAl‐Yafeai, Z., Horn, B. J. M., Terraccaine, W., Jose, A., & Krishnan, P. (2022) · Cureus · doi:10.7759/cureus.23162 · Cited by 15
“While these novel messenger ribonucleic acid (mRNA) and viral vector vaccines have undergone large clinical trials and are shown to be safe and effective, side effects may occur like other routine vaccines [1].”
BackgroundDynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study
Olariu, T. R., Ursoniu, S., Marincu, I., & Lupu, M. A. (2021) · Medicina · doi:10.3390/medicina57121330 · Cited by 14
“All study participants had been vaccinated with 2 doses of the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech, Mainz, Germany), 21 days apart [1].”
BackgroundMethodFujio, K., Sung, J., Nakatani, S., Yamamoto, K., Iwagami, M., Fujimoto, K., Shokirova, H., Okumura, Y., Akasaki, Y., Nagino, K., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154500 · Cited by 15
Speletas, M. G., Voulgaridi, I., Sarrou, S., Dadouli, K., Mouchtouri, V. Α., Nikoulis, D. J., Tsakona, M., Kyritsi, M. A., Peristeri, A.-M., Avakian, I., et al. (2022) · Vaccines · doi:10.3390/vaccines10020316 · Cited by 15
“The recommended vaccination schedule of BNT162b2 is an intramuscular administration of two 30 μg doses with an interval of 21 days between doses [4,5].”
BackgroundInfluentialMicroscopic Polyangiitis Following mRNA COVID-19 Vaccination: A Case Report
So, D., Min, K., Jung, W. Y., Han, S.-W., & Yu, M. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e154 · Cited by 16
Abdullahi, A., Frimpong, J. O., Cheng, M. T. K., Aliyu, S. H., Smith, C. J., Abimiku, A., Phillips, R. O., Owusu, M., & Gupta, R. K. (2023) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.23-0179 · Cited by 16
Sindet‐Pedersen, C., Michalik, F., Strange, J. E., Christensen, D. M., Nouhravesh, N., Gerds, T. A., Andersson, C., Folke, F., Biering‐Sørensen, T., Fosbøl, E. L., et al. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.010617 · Cited by 17
Bai, J., Chiba, A., Murayama, G., Kuga, T., Yahagi, Y., Tabe, Y., Tamura, N., & Miyake, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-24938-4 · Cited by 18
Recent Advances in Arboviral Vaccines: Emerging Platforms and Promising Innovations
Pujhari, S. K. (2023) · Biologics · doi:10.3390/biologics4010001 · Cited by 16
Cytosolic Delivery of Small Protein Scaffolds Enables Efficient Inhibition of Ras and Myc
Chan, A., Wang, H. H., Haley, R. M., Song, C., Gonzalez-Martinez, D., Bugaj, L. J., Mitchell, M. J., & Tsourkas, A. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00798 · Cited by 15
Tang, L., Zhang, Y., Wang, F., Wu, D., Qian, Z., Zhang, R., Wang, A., Huang, C., Wang, H., Ye, Y., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063919 · Cited by 17
COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK
Buckell, J., Jones, J. W., Matthews, P. C., Diamond, S. I., Rourke, E. D., Studley, R., Cook, D., Walker, A. S., Pouwels, K. B., the COVID-19 Infection Survey Team, et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-34244-2 · Cited by 24
Recomendaciones SEPAR sobre la vacuna COVID-19 en las enfermedades respiratorias
Álvarez, F. V., Martínez‐García, M. Á., Jiménez, D. G., Fariñas-Guerrero, F., de Lejarazu-Leonardo, R. O., López-Campos, J. L., Blanco‐Aparicio, M., Royo-Crespo, Í., García‐Ortega, A., García, A. T., et al. (2021) · Open Respiratory Archives · doi:10.1016/j.opresp.2021.100097 · Cited by 17
Key toolkits of non-pharmacological management in COPD: during and beyond COVID-19
Alqahtani, J. S., Alghamdi, S. M., Aldhahir, A. M., Althobiani, M. A., & Oyelade, T. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/4938 · Cited by 17
“Several trials have investigated the effect of multiple medications and newly developed vaccines, yielding conflicting results [5, 6].”
ResultKumbhar, P., Pandya, A., Manjappa, A. S., Disouza, J., & Patravale, V. B. (2021) · Carbohydrate Polymer Technologies and Applications · doi:10.1016/j.carpta.2021.100052 · Cited by 18
COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy
Wolf, A. B., & Álvarez, E. (2021) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000001088 · Cited by 15
“The spike protein is critical for cellular entry of SARS-CoV-2, and these vaccines have demonstrated about 95% protection against symptomatic COVID-19 infection over a 2-month period.(8,9)”
BackgroundGolshani, M., & Hrdý, J. (2022) · Vaccines · doi:10.3390/vaccines10020279 · Cited by 16
“However, injection with modified nucleotide mRNA COVID-19 vaccines may avoid this response [18,95,97,98].”
BackgroundZou, Y., Lu, J., Lian, Z., Jia, J., Shen, J., Li, Q., Wong, J. M. J., Jin, K., Yan, W., Ren, X.-Y., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072340 · Cited by 17
Peptides and peptidomimetics as therapeutic agents for Covid‐19
Dahal, A., Sonju, J. J., Kousoulas, K. G., & Jois, S. D. S. (2021) · Peptide Science · doi:10.1002/pep2.24245 · Cited by 17
Velasco, M., Galán, M. A., Casas, M. L. M. D. L., Pérez‐Fernández, E., Martínez-Ponce, D., González-Piñeiro, B., Castilla, V., Guijarro, C., Alcorcón COVID-19 Working Group, Weber, A. A., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab299 · Cited by 15
Anaphylaxis and Related Events Following COVID‐19 Vaccination: A Systematic Review
Paul, P., Janjua, E., Al-Subaie, M., Ramadorai, V., Mushannen, B., Vattoth, A. L., Khan, W., Bshesh, K., Nauman, A., Mohammed, I., et al. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2120 · Cited by 16
Yi, S. G., Moore, L. W., Eagar, T. N., Graviss, E. A., Nguyen, D. T., Ibrahim, H. N., Huang, H. J., Hobeika, M. J., McMillan, R. R., Saharia, A., et al. (2021) · Transplantation Direct · doi:10.1097/txd.0000000000001257 · Cited by 15
Classen, J. (2021) · Trends in Internal Medicine · doi:10.33425/2771-5906.1004 · Cited by 15
Race, trust, and COVID-19 vaccine hesitancy in people with opioid use disorder.
Sullivan, M. C., Mistler, C. B., Copenhaver, M. M., Wickersham, J. A., Ni, Z., Kim, R. S., & Shrestha, R. (2022) · Health Psychology · doi:10.1037/hea0001120 · Cited by 21
Safary, A., Akbarzadeh-Khiavi, M., Barar, J., & Omidi, Y. (2023) · Bioimpacts · doi:10.34172/bi.2023.27494 · Cited by 18
Widyasari, K., Jang, J., Lee, S. J., Kang, T., & Kim, S. (2022) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2022.09.004 · Cited by 15
Lyski, Z. L., Kim, M. S., Lee, D. X., Raué, H.-P., Raghunathan, V. M., Griffin, J., Ryan, D., Brunton, A. E., Curlin, M. E., Slifka, M. K., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006633 · Cited by 14
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.